TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6339294
Drug: fluprednylidene acetate/gentamicin/chlorohydroxyquinoline
Approvals — FDA: no, EMA: no, PMDA: no
Description: fluprednylidene acetate/gentamicin/chlorohydroxyquinoline cream
Study: 25223482
Drug: Epirubicin/cyclophosphamide followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin/cyclophosphamide followed by docetaxel with bevacizumab (8 infusions every 3 weeks)
Study: 25223482
Drug: Paclitaxel with
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel with everolimus (5 mg/day)
Study: 15383197
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg levofloxacin
Study: 15774257
Drug: 320/1600 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 320/1600 mg trimethoprim/sulfamethoxazole (TMP/SMZ)
Study: 11432680
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic prophylaxis (control group)
Study: 9660087
Drug: hCG/human menopausal
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG/human menopausal gonadotropin treatment in IHH patients
Study: 9660087
Drug: Testosterone treatment
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone treatment in Klinefelter's syndrome patients
Study: 2515720
Drug: Selegiline 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline 10 mg per day
Study: 24403903
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine (100 ml for women, 200 ml for men daily)
Study: 21450674
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 or 40 mg
Study: 21450674
Drug: Participants reaching
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants reaching 2.0 mmol/l LDL-C
Study: 19335418
Drug: Tacrolimus 0.03%
Normalized name: TACROLIMUS 0.03% OINT,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus 0.03% ointment (once-daily application)
Study: 19335418
Drug: Tacrolimus 0.03%
Normalized name: TACROLIMUS 0.03% OINT,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus 0.03% ointment (twice-daily application)
Study: 15236620
Drug: Amprenavir (APV)
DrugBank: Amprenavir (DB00701)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Amprenavir (APV) boosted with low-dose ritonavir (RTV, 100 mg bid)
Study: 15236620
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (SOC) protease inhibitors (PIs) with or without low-dose RTV
Study: 30314506
Drug: Conservative TMD
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative TMD treatment with a maximum of 18 sessions within 9 weeks
Study: 30314506
Drug: Delayed-start group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-start group (no treatment for 9 weeks)
Study: 21377273
Drug: ABT-102 4
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-102 4 mg twice a day
Study: 18755719
Drug: GEWF solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEWF solution preparation
Study: 14693069
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy based on chemosensitivity testing in nude mouse assay (Group I)
Study: 14693069
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen adjuvant chemotherapy (Group C) - cyclophosphamide (CTX) 600 mg/m² d1 + Adriamycin (ADM) 40 mg/m² d1 + cisplatin (DDP) 20 mg/m² d1-5
Study: 8642852
Drug: Idarubicin (IDA:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarubicin (IDA: 8 mg/m2/day, i.v. bolus for 5 days)
Study: 8642852
Drug: Daunorubicin (DNR:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daunorubicin (DNR: 50 mg/m2/day, i.v. bolus for 3 days)
Study: 23517382
Drug: Autologous noncultured
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous noncultured extracted hair follicle outer root sheath cell suspension (NCORSHFS)
Study: 20528823
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg/d for 3 days)
Study: 19059570
Drug: Weekly self-monitoring
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly self-monitoring of INR (group B)
Study: 19059570
Drug: Monthly laboratory
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly laboratory monitoring (group A)
Study: 19141327
Drug: Ciclesonide 160
Normalized name: CICLESONIDE 160MCG 60D ORAL INHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclesonide 160 microg once daily
Study: 12860365
Drug: Intramuscular olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular olanzapine (2.5-10 mg/injection)
Study: 12860365
Drug: Intramuscular haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular haloperidol (7.5 mg/injection)
Study: 11028256
Drug: terazosin 1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: terazosin 1, 2, and 5 mg
Study: 11028256
Drug: terazosin 2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: terazosin 2, 5, and 10 mg
Study: 11028256
Drug: terazosin 20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: terazosin 20, 40, and 80 mg
Study: 9365347
Drug: Elbow antagonists
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Elbow antagonists reversal exercise
Study: 1458667
Drug: 0.25% amorolfine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% amorolfine cream
Study: 1458667
Drug: 1% bifonazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% bifonazole cream
Study: 22419860
Drug: Iron isomaltoside
Normalized name: Iron isomaltoside 1000
DrugBank: Iron isomaltoside 1000 (DB12208)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron isomaltoside 1000 (100 mg)
Study: 22419860
Drug: Iron isomaltoside
Normalized name: Iron isomaltoside 1000
DrugBank: Iron isomaltoside 1000 (DB12208)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron isomaltoside 1000 (200 mg)
Study: 10925438
Drug: Methyl methacrylate
Normalized name: METHYL METHACRYLATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyl methacrylate implants
Study: 3086991
Drug: Rectal cultures
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal cultures
Study: 30075711
Drug: IRIS intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: IRIS intervention (Identification and Referral to Improve Safety) implemented in general practices; details on dosage and duration not specified.
Study: 17934527
Drug: Neuropsychological group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuropsychological group therapy
Study: 16516083
Drug: rHDL containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHDL containing low- or high-dose AIM
Study: 12663588
Drug: Magnesium supplementation
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium supplementation (50 ml MgCl(2) solution daily for 16 weeks)
Study: 9315990
Drug: Clonazepam 0.5
Normalized name: clonazepam 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam 0.5 mg
Study: 9315990
Drug: Clonazepam 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam 1.0 mg
Study: 9315990
Drug: Clonazepam 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam 2.0 mg
Study: 9315990
Drug: Clonazepam 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam 3.0 mg
Study: 9315990
Drug: Clonazepam 4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam 4.0 mg
Study: 2879477
Drug: tertatolol 5
Normalized name: tertatolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: tertatolol 5 mg
Study: 27234658
Drug: Oxycodone 30mg
Normalized name: oxycodone hydrochloride 30 MG [Roxicodone]
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone 30mg
Study: 27234658
Drug: Oxycodone 60mg
Normalized name: oxycodone hydrochloride 60 MG
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone 60mg
Study: 23378299
Drug: Low high-density
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low high-density lipoprotein cholesterol and insulin resistance phenotype
Study: 19801149
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Pravastatin (20 mg)
Study: 19801149
Drug: Co-therapy with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-therapy with Pravastatin
Study: 18507667
Drug: Test group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test group 1 (conventional drill preparation with immediate functional loading)
Study: 18507667
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard preparation procedure with submerged healing)
Study: 20546215
Drug: ingenol mebutate
Normalized name: Ingenol Mebutate
DrugBank: Ingenol mebutate (DB05013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ingenol mebutate gel, 0.05% (Arm A)
Study: 20546215
Drug: ingenol mebutate
Normalized name: Ingenol Mebutate
DrugBank: Ingenol mebutate (DB05013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ingenol mebutate gel, 0.0025% or 0.01% (Arm A)
Study: 20546215
Drug: vehicle gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: vehicle gel (Arm A and B)
Study: 20546215
Drug: ingenol mebutate
Normalized name: Ingenol Mebutate
DrugBank: Ingenol mebutate (DB05013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ingenol mebutate gel (Arm A)
Study: 16218171
Drug: IFN monotherapy
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN monotherapy (9 MU IFN‐alpha2a three times weekly)
Study: 16218171
Drug: IFN plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN plus RBV (1000‐1200 mg/day)
Study: 26918700
Drug: Controlled limited
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled limited formula (10 ml formula by syringe after each breastfeeding, discontinued at onset of lactation)
Study: 24202399
Drug: Hypokalemia interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypokalemia interventions administered pre-admission and post-operative
Study: 20693353
Drug: Aliskiren (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren (150 mg daily titrated to 300 mg daily after 3 months) added to 100 mg losartan
Study: 20693353
Drug: Placebo added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo added to 100 mg losartan
Study: 16904417
Drug: DMPA‐SC 104
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMPA‐SC 104 (104 mg/0.65 ml subcutaneous injection)
Study: 16904417
Drug: DMPA‐IM (intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMPA‐IM (intramuscular injection)
Study: 12534404
Drug: Etoricoxib (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib (120 mg once daily)
Study: 12534404
Drug: Ibuprofen (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (800 mg t.d.s.)
Study: 12848634
Drug: Naproxen (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (500 mg b.d.)
Study: 10491346
Drug: Nabumetone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabumetone (1 g)
Study: 7049706
Drug: Indapamide (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide (2.5 mg daily)
Study: 29596040
Drug: Antibiotic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic agents after I&D
Study: 24368224
Drug: Emtricitabine (FTC)
Normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Emtricitabine (FTC) 200 mg + Tenofovir disoproxil fumarate (TDF) 300 mg
Study: 22327492
Drug: HPV-16/18 AS04-adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV-16/18 AS04-adjuvanted vaccine (Cervarix)
Study: 18772704
Drug: Moderate-dose bifrontal
Normalized name: Bos taurus frontal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dose bifrontal ECT (BF)
Study: 18772704
Drug: Low-dose bitemporal
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose bitemporal ECT (BT)
Study: 9071516
Drug: LNG ROD
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNG ROD implants
Study: 9071516
Drug: Norplant-2 implants
Normalized name: Norplant 3-oxime
DrugBank: Norelgestromin (DB06713)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norplant-2 implants
Study: 2941770
Drug: Zimelidine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zimelidine (100 mg)
Study: 2941770
Drug: Maprotiline (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maprotiline (75 mg)
Study: 22157519
Drug: Olmesartan 40
Normalized name: HCTZ 25/OLMESARTAN 40MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan 40 mg per day
Study: 18000167
Drug: 5-drug induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-drug induction combination (including idarubicin, fludarabine, interleukin-2)
Study: 18000167
Drug: 5-drug reinduction
Normalized name: REDUCTIC ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-drug reinduction
Study: 98128
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg protirelin per day for 14 days
Study: 27036394
Drug: Extended-release niacin
Normalized name: niacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release niacin (ERN) plus simvastatin/ezetimibe
Study: 15649828
Drug: Total glycoalkaloid
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total glycoalkaloid (TGA) doses of 0.30 mg/kg BW
Study: 15649828
Drug: Total glycoalkaloid
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total glycoalkaloid (TGA) doses of 0.50 mg/kg BW
Study: 15649828
Drug: Total glycoalkaloid
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total glycoalkaloid (TGA) doses of 0.70 mg/kg BW
Study: 15649828
Drug: Mashed potatoes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mashed potatoes with TGA doses of 0.95 mg/kg BW
Study: 15649828
Drug: Mashed potatoes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mashed potatoes with TGA doses of 1.10 mg/kg BW
Study: 15649828
Drug: Mashed potatoes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mashed potatoes with TGA doses of 1.25 mg/kg BW
Study: 12678198
Drug: Trimetazidine (TMZ)
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (TMZ) plus dexrazoxane (DEX) (60 mg, daily dose)
Study: 9231815
Drug: Enalapril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (20 mg BID)
Study: 9231815
Drug: Nifedipine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (60 mg OD)
Study: 2259927
Drug: Oral tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tamoxifen citrate 10 mg twice daily
Study: 2259927
Drug: Oral megestrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral megestrol acetate 40 mg four times a day
Study: 7402688
Drug: Histamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine infusion at 0.16, 0.33, and 0.66 microgram/kg/min
Study: 7082501
Drug: Histamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine infusion
Study: 7402688
Drug: H1 blocking
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: H1 blocking agent (mepyramine)
Study: 6357892
Drug: Alclometasone dipropionate
Normalized name: Alclometasone Dipropionate
DrugBank: Alclometasone (DB00240)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alclometasone dipropionate cream 0.05%
Study: 6389385
Drug: Clobetasone butyrate
Normalized name: clobetasone butyrate
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Clobetasone butyrate cream 0.05%
Study: 27015295
Drug: Conventional combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional combination treatment (sulfasalazine plus hydroxychloroquine)
Study: 22378918
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate (target blood level 0.4‐0.8 mEq/l)
Study: 20631694
Drug: Hydrocortisone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (50 mg intravenously)
Study: 17016794
Drug: Tolterodine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine treatment for OAB over 12 weeks
Study: 15661432
Drug: Granisetron (5‐HT3‐antagonist)
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron (5‐HT3‐antagonist)
Study: 15661432
Drug: Diclofenac‐sodium (PGE2‐antagonist)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac‐sodium (PGE2‐antagonist)
Study: 10213211
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose paclitaxel (135 mg/m2, 24-h i.v. infusion)
Study: 10213211
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose paclitaxel (250 mg/m2, 24-h i.v. infusion)
Study: 10213211
Drug: Combined analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined analysis of paclitaxel concentrations from both treatment arms
Study: 655675
Drug: Long term
Normalized name: BENZETHONIUM CHLORIDE 0.12 g in 100 mL TOPICAL SOLUTION [CA-REZZ - LONG TERM CARE - INCONTINENT CLEANSER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long term 5-FU administered after postoperative irradiations for gastric cancer
Study: 655675
Drug: Levamisole as
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levamisole as adjuvant treatment for colon cancer
Study: 655675
Drug: Chemotherapy in
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy in advanced colon cancer
Study: 655675
Drug: Preoperative radiotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative radiotherapy for rectal cancer
Study: 655675
Drug: Chemotherapy as
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy as a preoperative irradiation sensitizer in rectal cancer
Study: 23559124
Drug: Salbutamol 800
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol 800 µg
Study: 19522395
Drug: Votalin Sustained
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Votalin Sustained Release Tablets
Study: 18091987
Drug: 1.0% C31G
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0% C31G (SAVVY) gel
Study: 8738073
Drug: i.v. meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. meperidine 100 mg
Study: 8738073
Drug: i.v. tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. tramadol 100 mg
Study: 1493086
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg glucagon from pancreatic extraction intramuscularly
Study: 1493086
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg genetically engineered glucagon intramuscularly
Study: 1493086
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g glucose intravenously
Study: 2859712
Drug: Astemizole, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astemizole, 10 mg on rising
Study: 2859712
Drug: Terfenadine, 60
Normalized name: Terfenadine, 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine, 60 mg on rising and in the evening
Study: 26710337
Drug: Pharmacogenetic warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacogenetic warfarin dosing
Study: 22056474
Drug: Lipid-lowering medication
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering medication
Study: 18813411
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate 50 mg daily for 60 days
Study: 14690101
Drug: Epidural levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural levobupivacaine 0.5% 15 mL
Study: 14690101
Drug: Epidural ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural ropivacaine 0.75% 15 mL
Study: 10733052
Drug: Metrifonate (60/80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metrifonate (60/80 mg)
Study: 10733052
Drug: Metrifonate (40/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metrifonate (40/50 mg)
Study: 8604962
Drug: Active antihypertensive
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active antihypertensive drug therapy
Study: 29280723
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy with adjustment of challenge-skill balance
Study: 29280723
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy without adjustment of challenge-skill balance
Study: 15856076
Drug: metoclopramide (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoclopramide (up to 40 mg/day)
Study: 15856076
Drug: naproxen (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen (up to 1000 mg/day)
Study: 14716965
Drug: Fluticasone/salmeterol combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone/salmeterol combination 250/50 micrograms one inhalation twice daily
Study: 14716965
Drug: CFC beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: CFC beclomethasone dipropionate 250 micrograms two puffs twice daily plus montelukast 10 mg in the evening
Study: 15537846
Drug: Non-selective beta-blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-selective beta-blockers
Study: 15537846
Drug: Novel therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel therapies targeting intrahepatic resistance
Study: 9046455
Drug: Stretching exercises
Normalized name: Mederma Stretch Mark Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stretching exercises (two unsupervised sessions daily over the same time period)
Study: 905580
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg PGE2 vaginal suppositories